MCC950 ameliorates ventricular arrhythmia vulnerability induced by heart failure

Area of Science:

• Cardiovascular Research
• Molecular Cardiology
• Inflammation and Immunity

Background:

• Heart failure (HF) often leads to ventricular arrhythmias (VAs), posing a significant clinical challenge.
• The role of the NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome in HF-induced VAs is not fully understood.

Purpose of the Study:

• To investigate the therapeutic potential of MCC950, a specific NLRP3 inhibitor, in mitigating HF-induced VAs.
• To elucidate the underlying mechanisms by which MCC950 affects cardiac structure and electrical activity in a heart failure model.

Main Methods:

• Male C57BL/6 mice underwent transverse aortic constriction (TAC) to induce HF.
• Evaluations included histological analysis, echocardiography, electrophysiological studies, and western blot analysis.
• Mice were treated with MCC950 to assess its effects on VA vulnerability and cardiac remodeling.

Main Results:

• MCC950 treatment significantly improved cardiac function and reduced pulmonary edema in HF mice.
• VA vulnerability was decreased, evidenced by shortened QTc duration, APD90, and reduced APD alternans threshold.
• MCC950 reversed TAC-induced cardiac hypertrophy and fibrosis, and increased key ion channel protein levels (Kv4.2, KChIP2, Cav1.2).

Conclusions:

• MCC950 effectively reduces HF-induced VA vulnerability by inhibiting NLRP3 inflammasome activation.
• The protective effects involve reversing cardiac structural and electrical remodeling.
• MCC950 demonstrates significant therapeutic promise for managing arrhythmias in heart failure.